LAVA Therapeutics gets FDA orphan drug status for LAVA-051 in CLL
LAVA Therapeutics has been granted orphan drug designation (ODD) in chronic lymphocytic leukemia (CLL) from the US Food and Drug Administration (FDA) for LAVA-051, its CD1d-targeted Gammabody. According to the US-based biotech company, LAVA-051 is a bispecific antibody that triggers the immune system to target cancer cells that express CD1d through the selective activation of […]